US Patent Issued to ELLIPSES PHARMA, INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) on May 12 for "Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-bpyridine" (British Inventors)

ALEXANDRIA, Va., May 12 -- United States Patent no. 12,624,027, issued on May 12, was assigned to ELLIPSES PHARMA LTD (London) and INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (London).

"Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-bpyridine" was invented by Jonathan Loughrey (Midlothian, Great Britain), Natalie Kelk (Midlothian, Great Britain), Michaela Kreiner (Glasgow, Great Britain) and Gavin Halbert (Glasgow, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to salts and polymorphic forms of Compound A (6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyra...